Empro Group Inc. Ordinary shares (EMPG)vsNovartis AG ADR (NVS)
EMPG
Empro Group Inc. Ordinary shares
$17.36
0.00%
HEALTHCARE · Cap: $143.05M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1031461% more annual revenue ($56.58B vs $5.48M). NVS leads profitability with a 23.9% profit margin vs 13.7%. NVS trades at a lower P/E of 21.2x. NVS earns a higher WallStSmart Score of 51/100 (C-).
EMPG
Hold47
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EMPG.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 66 in profit
Strong operational efficiency at 36.1%
Revenue surging 141.6% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 17.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : EMPG
The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : EMPG
The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
EMPG profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
EMPG is growing revenue faster at 141.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 47/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Empro Group Inc. Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?